Transdermal and buccal delivery of methylxanthines through human tissue in vitro

Drug Development and Industrial Pharmacy

Volumn 33, Issue 5, 2007, Pages 513-521

  Thakur, Rashmi A ^a   Michniak, Bozena B ^a   Meidan, Victor M ^b  

^a RUTGERS UNIVERSITY   (United States)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Buccal; Caffeine; Oleic acid; Terpenes; Theobromine; Theophylline; Transdermal

Indexed keywords

CAFFEINE; CENTRAL STIMULANT AGENT; CINEOLE; LAUROCAPRAM; LIMONENE; MENTHONE; METHYLXANTHINE; OLEIC ACID; SOLVENT; TERPINEOL; THEOBROMINE; THEOPHYLLINE;

ADULT; AGED; ARTICLE; DRUG SOLUBILITY; DRUG TRANSPORT; HUMAN; HUMAN TISSUE; IN VITRO SELECTION; MALE; MEMBRANE PERMEABILITY; SKIN PERMEABILITY;

ADMINISTRATION, BUCCAL; ADMINISTRATION, CUTANEOUS; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; EXCIPIENTS; HUMANS; MOUTH MUCOSA; OLEIC ACID; PERMEABILITY; SKIN; SKIN ABSORPTION; SOLUBILITY; THEOBROMINE; THEOPHYLLINE; XANTHENES;

EID: 34249313357     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040600901994     Document Type: Article

References (31)

1. Akomeah, F., Nazir, T., Martin, G. P., & Brown, M. B. (2004). Effect of heat on the percutaneous absorption and skin retention of three model penetrants. Eur. J. Pharm. Sci., 21, 337-345.
2. Aungst, B. (1995). Fatty alcohols as skin permeation enhancers. In: Percutaneous Penetration Enhancers. Eds.: E. W. Smith and H. I. Maibach. CRC Press, Boca Raton, pp. 277.
3. Babu, R. J., Singh, M., & Kanikkannan, N. (2006). Fatty alcohols and fatty acids. In: Percutaneous Penetration Enhancers. Eds.: S. E.W. and H. I. Maibach. CRC Press, Boca Raton, pp. 137.
4. Batchelder, R. J., Calder, R. J., Thomas, C. P., & Heard, C. M. (2004). In vitro transdermal delivery of the major catechins and caffeine from extract of Camellia sinensis. Int. J. Pharm., 283, 45-51.
5. Benowitz, N. L. (1995). Nicotine patches. BMJ, 310, 1409-1410.
6. Dias, M., Farinha, A., Faustino, E., Hadgraft, J., Pais, J., & Toscano, C. (1999). Topical delivery of caffeine from some commercial formulations. Int. J. Pharm., 182, 41-47.
7. El-Kattan, A. F., Asbill, C. S., Kim, N., & Michniak, B. B. (2001). The effects of terpene enhancers on the percutaneous permeation of drugs with different lipophilicities. Int. J. Pharm., 215, 229-240.
8. Flynn, G. L. & Stewart, B. (2004). Percutaneous drug penetration: Choosing candidates for transdermal development. Drug Dev. Res., 13, 169-185.
9. Gabiga, H., Cal, K., & Janicki, S. (2000). Effect of penetration enhancers on isosorbide dinitrate penetration through rat skin from a transdermal therapeutic system. Int. J. Pharm., 199, 1-6.
10. Hansch, C., Hoekman, D., Leo, A., Weininger, D., & Selassie, C. D. (2002). Chem-bioinformatics: comparative QSAR at the interface between chemistry and biology. Chem. Rev., 102, 783-812.
11. http://www.mattek.com.
12. Jiang, S. J. & Zhou, X. J. (2003). Examination of the mechanism of oleic acid-induced percutaneous penetration enhancement: an ultrastructural study. Biol. Pharm. Bull., 26, 66-68.
13. Kim, D. D. & Chien, Y. W. (1995). Transdermal delivery of zalcitabine: in vitro skin permeation study. Aids, 9, 1331-1336.
14. Langoth, N., Kalbe, J., & Bernkop-Schnurch, A. (2005). Development of a mucoadhesive and permeation enhancing buccal delivery system for PACAP (pituitary adenylate cyclase-activating polypeptide). Int. J. Pharm., 296, 103-111.
15. Larrucea, E., Arellano, A., Santoyo, S., & Ygartua, P. (2001). Combined effect of oleic acid and propylene glycol on the percutaneous penetration of tenoxicam and its retention in the skin. Eur. J. Pharm. Biopharm., 52, 113-119.
16. Lee, J. & Kellaway, I. W. (2000). Combined effect of oleic acid and polyethylene glycol 200 on buccal permeation of [D-ala2, Dleu5] enkephalin from a cubic phase of glyceryl monooleate. Int. J. Pharm., 204, 137-144.
17. Lee, P. J., Ahmad, N., Langer, R., Mitragotri, S., & Prasad Shastri, V. (2006). Evaluation of chemical enhancers in the transdermal delivery of lidocaine. Int. J. Pharm., 308, 33-39.
18. Lee, P. J., Langer, R., & Shastri, V. P. (2005). Role of n-methyl pyrrolidone in the enhancement of aqueous phase transdermal transport. J. Pharm. Sci., 94, 912-917.
19. Mandel, H. G. (2002). Update on caffeine consumption, disposition and action. Food Chem. Toxicol., 40, 1231-1234.
20. Meidan, V. M. & Michniak, B. B. (2004). Emerging technologies in transdermal therapeutics. Am. J. Ther., 11, 312-316.
21. Moser, K., Kriwet, K., Naik, A., Kalia, Y. N., & Guy, R. H. (2001). Passive skin penetration enhancement and its quantification in vitro. Eur. J. Pharm. Biopharm., 52, 103-112.
22. Narishetty, S. T. & Panchagnula, R. (2004). Transdermal delivery system for zidovudine: in vitro, ex vivo and in vivo evaluation. Biopharm. Drug Dispos., 25, 9-20.
23. Nicolazzo, J. A., Reed, B. L., & Finnin, B. C. (2005). Buccal penetration enhancers - how do they really work? J. Control. Release, 105, 1-15.
24. Nicoli, S., Amoretti, V., Colombo, P., & Santi, P. (2004). Bioadhesive transdermal film containing caffeine. Skin Pharmacol. Physiol., 17, 119-123.
25. Nicoli, S., Colombo, P., & Santi, P. (2005). Release and permeation kinetics of caffeine from bioadhesive transdermal films. AAPS J., 7, E218-223.
26. Nyberg, G. (1986). Onset time of action and duration up to 3 hours of nitroglycerin in buccal, sublingual and transdermal form. Eur. Heart J., 7, 673-678.
27. Oh, H. J., Oh, Y. K., & Kim, C. K. (2001). Effects of vehicles and enhancers on transdermal delivery of melatonin. Int. J. Pharm., 212, 63-71.
28. Rowat, A. C., Kitson, N., & Thewalt, J. L. (2006). Interactions of oleic acid and model stratum corneum membranes as seen by (2)H NMR. Int. J. Pharm., 307, 225-231.
29. Tanojo, H., Bouwstra, J. A., Junginger, H. E., & Bodde, H. E. (1997). In vitro human skin barrier modulation by fatty acids: skin permeation and thermal analysis studies. Pharm. Res., 14, 42-49.
30. Tiplady, B., Fagan, D., Lamont, M., Brockway, M., & Scott, D. B. (1990). A comparison of the CNS effects of enprofylline and theophylline in healthy subjects assessed by performance testing and subjective measures. Br. J. Clin. Pharmacol., 30, 55-61.
31. Vavrova, K., Hrabalek, A., Dolezal, P., Holas, T., & Klimentova, J. (2005). Biodegradable derivatives of tranexamic acid as transdermal permeation enhancers. J. Control. Release, 104, 41-49.